![Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial ... Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial ...](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f66b463d-0f51-429c-8a3b-87531356ab5d/gr3a_lrg.gif)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial ...
![Tiger, Volume 20, 1967 - Images of Oklahoma - Oklahoma Digital Prairie: Documents, Images and Information Tiger, Volume 20, 1967 - Images of Oklahoma - Oklahoma Digital Prairie: Documents, Images and Information](https://digitalprairie.ok.gov/digital/api/singleitem/image/p16807coll1/84410/default.jpg)